Gene therapy trials for incurable diseases are being delayed for years because the UK lacks the facilities to manufacture the clinical-grade viruses that deliver the treatments. Gene therapies use engineered viruses as delivery vehicles to carry corrective genes into patients’ cells. In research labs, scientists can produce small batches of these viruses to test in animal models. But moving to human trials requires large quantities of virus manufactured to strict quality standards—known as Good Manufacturing Practice (GMP). The UK has too few such facilities, and existing ones cannot keep up with demand from university-led research. This bottleneck is blocking promising discoveries from reaching patients with conditions that conventional drugs cannot treat. The Gene Therapy Innovation and Manufacturing Centre (GTIMC) will build a new state-of-the-art GMP facility to fill this gap. It will also develop improved viral vectors, boost manufacturing yields, and provide regulatory and training support. If successful, the centre will accelerate the translation of fundamental gene therapy research into clinical trials, create skilled jobs, and help spin out new biotech companies. The project addresses a critical infrastructure shortage, not a scientific unknown—it is about removing a practical barrier to patient benefit.
View original technical description
Gene therapies rely on engineered virus carriers as vehicles for the delivery of synthetic genes that allow correction of disease-altered changes in multiple organs of the human body. Viruses exploited in gene therapy approaches have been modified to remove harmful properties and carry the therapeutic gene of interest. Multiple gene therapy programmes are currently undertaken in research laboratories using relatively small-scale production of viruses which enables optimisation of the doses and administration routes as well as testing for the safety and therapeutic efficacy of interventions in animal models of disease. However, facilities required for the production of large quantities of clinical-grade viruses of consistent quality-controlled GMP grade are rare in the UK. Thus, it can easily take several years before clinical trials can be conducted. Currently, existing facilities cannot meet the escalating demand of academically-led research needs for clinical-grade virus carriers. This is significantly obstructing numerous UK-funded world-leading disease-modifying discoveries to be translated into clinical trials for human benefit. The lack of suitable GMP facilities seriously hinders the development of much-needed novel effective treatments for multiple incurable diseases which cannot be treated by conventional drug compounds. We propose to address the manufacturing shortage by creating a Gene Therapy Innovation and Manufacturing Centre (GTIMC) which includes provision of a new state-of-the-art GMP manufacturing facility to support gene therapy projects emerging from UK universities. GTIMC will also support the development of improved viral vectors, improved yield from the manufacturing process and will also provide essential regulatory and training support. Moreover, the GTIMC hub will allow new training and high-skilled employment opportunities through the ShefVec facility itself, and future start-up companies.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know